Natalizumab discontinuation in a Dutch real-world cohort

被引：3
|
作者：
Coerver, E. M. E. [1 ]
Wessels, M. H. J. [1 ]
van Lierop, Z. Y. G. [1 ]
van Kempen, Z. L. E. [1 ]
Killestein, J. [1 ]
Strijbis, E. M. M. [1 ]
机构：
[1] Vrije Univ Amsterdam, MS Ctr Amsterdam, Amsterdam Neurosci, Dept Neurol,Amsterdam Univ Med Ctr, Amsterdam, Netherlands
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2021年 / 52卷
关键词：
Multiple sclerosis; Natalizumab; Treatment discontinuation; MS;
D O I：
10.1016/j.msard.2021.102974
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Natalizumab discontinuation in a dutch real-world cohort
    Coerver, E.
    Wessels, M.
    Van Lierop, Z.
    Van Kempen, Z.
    Killestein, J.
    Strijbis, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 347 - 348
  • [2] Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
    Juliette Pelle
    Anais R. Briant
    Pierre Branger
    Nathalie Derache
    Charlotte Arnaud
    Christine Lebrun-Frenay
    Mikael Cohen
    Lydiane Mondot
    Jerome De Seze
    Kevin Bigaut
    Nicolas Collongues
    Laurent Kremer
    Damien Ricard
    Flavie Bompaire
    Charlotte Ohlmann
    Magali Sallansonnet-Froment
    Jonathan Ciron
    Damien Biotti
    Beatrice Pignolet
    Jean-Jacques Parienti
    Gilles Defer
    Neurology and Therapy, 2023, 12 : 529 - 542
  • [3] Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
    Pelle, Juliette
    Briant, Anais R.
    Branger, Pierre
    Derache, Nathalie
    Arnaud, Charlotte
    Lebrun-Frenay, Christine
    Cohen, Mikael
    Mondot, Lydiane
    De Seze, Jerome
    Bigaut, Kevin
    Collongues, Nicolas
    Kremer, Laurent
    Ricard, Damien
    Bompaire, Flavie
    Ohlmann, Charlotte
    Sallansonnet-Froment, Magali
    Ciron, Jonathan
    Biotti, Damien
    Pignolet, Beatrice
    Parienti, Jean-Jacques
    Defer, Gilles
    NEUROLOGY AND THERAPY, 2023, 12 (02) : 529 - 542
  • [4] Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience
    Bergmeijer, Thomas O.
    Janssen, Paul W. A.
    van Oevelen, Mathijs
    van Rooijen, Dymphie
    Godschalk, Thea C.
    Kelder, Johannes C.
    Deneer, Vera H. M.
    Serebruany, Victor L.
    ten Berg, Jurrien M.
    CARDIOLOGY, 2017, 138 (03) : 164 - 168
  • [5] REAL-WORLD OUTCOMES AFTER VEDOLIZUMAB DISCONTINUATION IN A TERTIARY IBD COHORT
    Sebepos-Rogers, Gregory
    Fragkos, Konstantinos
    Saravanapavan, Hajeena
    Barragry, John
    Koo, Hui Fen
    Ko, Ho Juen
    Parisi, Ioanna
    Seward, Edward
    McCartney, Sara
    Bloom, Stuart
    Mehta, Shameer
    Rahman, Farooq
    GUT, 2021, 70 : A81 - A82
  • [6] Fingolimod Discontinuation Rate and Characteristics of Disease Activity in Real-world Cohort
    Esfahani, Neda Zarghami
    vonGeldern, Gloria
    Romba, Meghan
    Persenaire, Michael
    Wundes, Annette
    NEUROLOGY, 2020, 94 (15)
  • [7] Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
    Evdoshenko, Evgeniy
    Stepanova, Alexandra
    Shumilina, Maria
    Davydovskaya, Maria
    Khachanova, Natalia
    Neofidov, Nikolay
    Kalinin, Ivan
    Popova, Ekaterina
    Dubchenko, Ekaterina
    Pozhidaeva, Natalia
    Volkov, Andrey
    Sivertseva, Stella
    Prilenskaya, Anna
    Malkova, Nadezhda
    Korobko, Denis
    Vergunova, Ilona
    Shchur, Sergey
    Makshakov, Gleb
    PLOS ONE, 2019, 14 (05):
  • [8] Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort study
    van de Ree-Pellikaan, Claire
    de Kreuk, Arne
    Schaar, Cees G.
    Beeker, Aart
    Dompeling, Ellen C.
    Gerrits, Cees J. H.
    van Houten, Anja A.
    Schipperus, Martin R.
    Strobbe, Leonie
    Posthuma, Eduardus F. M.
    Klauke, Karin
    Westerweel, Peter E.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (05) : 453 - 459
  • [9] Benefits of early treatment with natalizumab: a real-world study
    Ontaneda, Daniel
    Mowry, Ellen M.
    Newsome, Scott D.
    Naismith, Robert T.
    Nicholas, Jacqueline
    Fisher, Elizabeth
    de Moor, Carl
    Bohn, Justin
    Ho, Pei-Ran
    Sandrock, Al
    Rudick, Richard
    Williams, James R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [10] Benefits of early treatment with natalizumab: a real-world study
    Ontaneda, Daniel
    Mowry, Ellen M.
    Newsome, Scott D.
    Naismith, Robert T.
    Nicholas, Jacqueline
    Fisher, Elizabeth
    de Moor, Carl
    Bohn, Justin
    Ho, Pei-Ran
    Sandrock, Al
    Rudick, Richard
    Williams, James R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
12345